Exclusive Summary

• - Off-patent globally and US-registered injection enables rapid access via reliance pathways and hospital channels in multiple regions.
• - Serves ≈300–350 million adults with IBS for short-term control of acute GI spasm when oral therapy is not feasible, supporting steady inpatient/ED demand.
• - Antispasmodics are guideline-supported for short-term relief; dicyclomine is an adjunct/second-line option, not on WHO EML but available as a US injection.
• - Few injectable competitors worldwide (historically only a small number of US ANDA holders), differentiating through US approval, compliance, and reliable supply.
• - Generic pricing typically delivers ~50–80% savings vs originator, fitting tender-driven and hospital cost-containment needs.